Key result
The VerifyNow P2Y12 point-of-care assay can rapidly measure platelet inhibition in patients taking clopidogrel, identifying poor responders and potentially guiding changes in therapy.
The VerifyNow P2Y12 assay is a point-of-care device that can rapidly measure platelet inhibition in patients taking clopidogrel, potentially identifying poor responders and guiding therapy changes.
May enable point-of-care detection of clopidogrel nonresponders; leaves open whether assay-guided adjustments improve outcomes.
Clopidogrel is an important component of medical therapy for patients with acute coronary syndromes and those receiving coronary stents. Despite the use of clopidogrel, a significant number of patients experience recurrent adverse ischemic events. Inter-individual variability of platelet aggregation in response to clopidogrel may provide an explanation for some of these recurrent events, and small trials have linked clopidogrel resistance, as measured by platelet function tests, to adverse events. The VerifyNow P2Y12 assay (Accumetrics, Inc., CA, USA) is a point-of-care device that can accurately and rapidly measure the degree of platelet inhibition in patients taking clopidogrel. This assay can identify patients with a poor response to clopidogrel, and could potentially lead to change in therapy.
No takes yet. Share an insight, caveat, or question.
McLean et al. (2006) conducted a review in Acute coronary syndromes and patients receiving coronary stents taking clopidogrel. VerifyNow P2Y12 assay was evaluated. The VerifyNow P2Y12 point-of-care assay can rapidly measure platelet inhibition in patients taking clopidogrel, identifying poor responders and potentially guiding changes in therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: